Herikin

Herikîn is an Australian biotechnology firm positioned to address a critical bottleneck in the life sciences sector: the slow and complex process of RNA synthesis. The company is developing what it terms the first desktop RNA printer, an automated manufacturing platform designed to significantly shorten the production timeline for RNA from months to a single week. This is accomplished through a proprietary combination of next-generation continuous-flow fluidics, advanced bioprocess engineering, and integrated hardware systems.

The company was founded by Harry Al-Wassiti. Herikîn's technology targets a key market of scientists and clinicians who require rapid and scalable access to RNA for research and therapeutic development. The platform is engineered to handle not just production, but also purification and quality control, offering an end-to-end solution. By decentralizing and automating this capability, the company aims to accelerate the pace of scientific discovery and the adoption of RNA-based technologies.

Having emerged from the UNSW Founders accelerator program, Herikîn has secured backing from venture capital, including Radar Ventures. The company has successfully developed a functional minimum viable product (MVP) and, as of late 2024, was proceeding with customer testing at three sites in Melbourne and Sydney. A full market launch of its RNA printer technology is anticipated for 2025. Keywords: RNA printer, biomanufacturing, RNA synthesis, desktop RNA production, automated bioprocessing, biotechnology, life sciences, next-generation fluidics, enzymatic engineering, RNA manufacturing, scientific research tools, clinical tools, UNSW Founders, Harry Al-Wassiti, Radar Ventures, biopharma, healthtech, advanced manufacturing, RNA technology, lab automation, nucleic acid synthesis, therapeutic RNA